Brightpath Biotherapeutics Co., Ltd.
Records under this name other than the patents Brightpath Biotherapeutics Co., Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Back to Brightpath Biotherapeutics Co., Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,642,900 | CTL inducer composition Lapsed on the fee record Ended May 9, 2025 · From the USPTO record | Lapsed on the fee record | Ended May 9, 2025 | From the USPTO record |
| US 7,655,751 | Epidermal growth factor receptor-derived peptides Term ended Term ended Mar 13, 2025 · From the USPTO record | Term ended | Term ended Mar 13, 2025 | From the USPTO record |
| US 9,505,824 | Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation Lapsed on the fee record Ended Nov 29, 2024 · From the USPTO record | Lapsed on the fee record | Ended Nov 29, 2024 | From the USPTO record |
| US 9,102,715 | CTL inducer composition Lapsed on the fee record Ended Aug 11, 2023 · From the USPTO record | Lapsed on the fee record | Ended Aug 11, 2023 | From the USPTO record |
| US 7,465,452 | Tumor antigen Term ended Term ended Sep 27, 2022 · From the USPTO record | Term ended | Term ended Sep 27, 2022 | From the USPTO record |
| US 7,148,326 | Tumor Antigen Term ended Term ended Aug 31, 2022 · High confidence | Term ended | Term ended Aug 31, 2022 | High confidence |
| US 7,524,930 | Tumor Antigen Term ended Term ended Apr 7, 2022 · High confidence | Term ended | Term ended Apr 7, 2022 | High confidence |
| US 7,404,270 | Tumor Antigen Term ended Term ended Jul 30, 2021 · High confidence | Term ended | Term ended Jul 30, 2021 | High confidence |
| US 7,408,037 | Tumor Antigen Term ended Term ended Jul 30, 2021 · High confidence | Term ended | Term ended Jul 30, 2021 | High confidence |
| US 7,427,660 | Tumor Antigen Term ended Term ended Jul 30, 2021 · High confidence | Term ended | Term ended Jul 30, 2021 | High confidence |